Last reviewed · How we verify
MP-513 Medium Dose and Metformin
MP-513 Medium Dose and Metformin is a Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 2 development.
At a glance
| Generic name | MP-513 Medium Dose and Metformin |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MP-513 Medium Dose and Metformin CI brief — competitive landscape report
- MP-513 Medium Dose and Metformin updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI
Frequently asked questions about MP-513 Medium Dose and Metformin
What is MP-513 Medium Dose and Metformin?
MP-513 Medium Dose and Metformin is a Small molecule drug developed by Tanabe Pharma Corporation.
Who makes MP-513 Medium Dose and Metformin?
MP-513 Medium Dose and Metformin is developed by Tanabe Pharma Corporation (see full Tanabe Pharma Corporation pipeline at /company/tanabe-pharma-corporation).
What development phase is MP-513 Medium Dose and Metformin in?
MP-513 Medium Dose and Metformin is in Phase 2.